SynthesisAbdominal radiology (New York)2021
LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.
Synthesis in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- LR-TR viable as an early imaging indicator of local recurrence after radiofrequency ablation for hepatocellular carcinoma: a longitudinal assessment using LI-RADS nonradiation TRA version 2024.Japanese journal of radiology · 2026Article
- The 2024 LI-RADS treatment response update: practical reporting after non-radiation and radiation locoregional therapies for hepatocellular carcinoma.Insights into imaging · 2026Review
- Current State of Evidence for Use of MRI in LI-RADS.Journal of magnetic resonance imaging : JMRI · 2025Review
- Association of LR treatment response category with outcome of patients with hepatocellular carcinoma on explant pathology.Abdominal radiology (New York) · 2025Article
- Accuracy of cross-sectional imaging in predicting tumor viability using the LI-RADS treatment response algorithm after image-guided percutaneous ablation with radiologic-pathologic explant correlation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- LI-RADS CT/MRI Treatment Response Assessment Update in 2024.Journal of the Korean Society of Radiology · 2025Review
- CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.Radiology · 2024Review
- Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation.Life (Basel, Switzerland) · 2023Review
- Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.Journal of magnetic resonance imaging : JMRI · 2023Review
- Clinical Significance of Liver MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2023Review
- LI-RADS: Looking Back, Looking Forward.Radiology · 2023Review
- [CT/MRI Liver Imaging Reporting and Data System (LI-RADS): Standardization, Evidence, and Future Direction].Journal of the Korean Society of Radiology · 2023Review
- LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies.Taehan Yongsang Uihakhoe chi · 2022Article
- CLEC14A was up-regulated in hepatocellular carcinoma and may function as a potential diagnostic biomarker.Clinics (Sao Paulo, Brazil) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeTo perform a systematic review and meta-analysis using individual patient data to investigate the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) Treatment Response (TR) algorithm for detecting incomplete necrosis on pathology.
methodsPubMed and EMBASE were searched from Jan 1, 2017 until October 14, 2020. Studies reporting diagnostic accuracy of LI-RADS TR algorithm on CT or MRI for detecting incomplete necrosis on pathology as a reference standard were included. Sensitivity and specificity were pooled using random-effects model. Subgroup analyses were performed for locoregional treatment (LRT) type and imaging modality.
resultsSix studies (393 patients, 534 lesions) were included. Pooled sensitivity was 0.56 (95% confidence interval [CI] 0.43-0.69) and specificity was 0.91 (95%CI 0.84-0.96). Pooled sensitivity was highest using arterial phase hyperenhancement (APHE) (0.67 [95%CI 0.51-0.81]), followed by washout (0.43 [95%CI 0.26-0.62]) and enhancement similar to pretreatment (0.24 [95%CI 0.15-0.36]). Among lesions with incomplete necrosis, 2% (95%CI 0.00-0.05) manifested as washout but no APHE; 0% (95% CI 0.00-0.02) as enhancement similar to pretreatment without both APHE and washout. Pooled sensitivity was lower after ablation than embolization (0.42 [95%CI, 0.28-0.57] vs. 0.65 [95%CI, 0.53-0.77], p = 0.033). MRI and CT were comparable (p = 0.783 and 0.290 for sensitivity and specificity).
conclusionsLI-RADS TR algorithm shows moderate sensitivity and high specificity for detecting incomplete necrosis after LRT. APHE is the dominant criterion, a washout contributes to small but meaningful extent, while the contribution of enhancement similar to pretreatment may be negligible. LRT type may affect performance of the algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.